SCHEMBL14328397

SCHEMBL14328397

CNc1cc(F)ccc1N1CCC(NC)(C(N)=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ERAP1 Q9NZ08 1/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CYP2C19 P33261 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ NOTUM Q6P988 1/20 0.35
▸ IKBKB O14920 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ WDR5 P61964 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14206538 0.86 ALDH1A1 (0.52) THRBKDM4EKMT2AALDH1A1L3MBTL1
SCHEMBL13322705 0.82 ALDH1A1 (0.42) KDM4EKMT2AALDH1A1L3MBTL1CYP2C19
SCHEMBL14328407 0.81 KDM4E (0.36) THRBKDM4EKMT2AALDH1A1CYP2D6
SCHEMBL14328971 0.78 OPRK1 (0.36) KDM4EKMT2ACNR1SMN1; SMN2
SCHEMBL14328974 0.78 GSK3B (0.46) KDM4EKMT2ACNR1MAPT
SCHEMBL14328409 0.75 KMT2A (0.37) KDM4EKMT2AALDH1A1L3MBTL1CYP2D6
SCHEMBL14206526 0.74 KDM4E (0.39) THRBKDM4EKMT2AALDH1A1L3MBTL1
SCHEMBL10151530 0.74 ALDH1A1 (0.54) THRBKMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL18600293 0.73 CHEK1 (0.40) SMN1; SMN2
SCHEMBL14206461 0.73 CHEK1 (0.56) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 — — US disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 — — US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 — — US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 THRB 2605/4885KDM4E 3595/4885KMT2A 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback